NCT06652100 (EPACRA-AKI) is a clinical trial of ProNephro AKI (NGAL) in Acute Kidney Injury, sponsored by BioPorto Diagnostics.

Who is sponsoring NCT06652100?

NCT06652100 is sponsored by BioPorto Diagnostics.

What drugs are being tested in NCT06652100?

Interventions in NCT06652100: ProNephro AKI (NGAL).

What condition does NCT06652100 study?

NCT06652100 studies Acute Kidney Injury.

Is NCT06652100 still recruiting?

NCT06652100 is currently active, enrolled. Last updated 19 November 2025.

Last reviewed 2025-11-19 · How we verify

NCT06652100: EPACRA-AKI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Active, enrolled Last updated 19 November 2025

What this trial tests

trial testing ProNephro AKI (NGAL) in Acute Kidney Injury in 800 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 October 2024

Primary endpoint
30 January 2026

31 January 2026

Quick facts

Lead sponsor	BioPorto Diagnostics
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	800
Start date	28 October 2024
Primary completion	30 January 2026
Estimated completion	31 January 2026
Sites	12 locations across United States

Drugs / interventions tested

ProNephro AKI (NGAL)

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

BioPorto Diagnostics

Who can join

22 and older, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Implementation of Urinary Neutrophil Gelatinase-Associated Lipocalin Testing for Diagnosing Acute Kidney Injury in an Academic Tertiary Care Medical Centre.
Strader M, Imran S, Tariq A, Fraser C, et al · · 2025 · cited 2× · PMID 40802457 · DOI 10.34067/kid.0000000887

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06652100 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioPorto Diagnostics
Last refreshed: 19 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06652100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing